# Off-the-shelf KRAS vaccines after pancreatic cancer surgery

Source: https://onco.cc/ideas/idea-shared-kras-vaccine-adjuvant/  
OnCo record `idea-shared-kras-vaccine-adjuvant` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Almost every pancreatic cancer shares one of a handful of KRAS mutations. A pre-made vaccine against them could be given to every patient after surgery.

## Summary

Almost every pancreatic cancer carries one of a handful of KRAS mutations, so this idea gives a pre-made KRAS vaccine to every patient after surgery, enriching for MRD-positive disease. Tumour burden is low after resection, the neoantigen is shared, ctDNA can enrich and monitor, and RAS inhibitors such as daraxonrasib may increase antigen presentation. ELI-002 7P from Elicio induced KRAS-specific T cells in phase 1 and is in the randomised AMPLIFY-7P phase 2, whereas personalised vaccines such as autogene cevumeran work but take weeks and cost more. The test is a phase 2/3 with ctDNA-positive enrichment and a recurrence-free survival endpoint. At early-clinical maturity it addresses the bottleneck The undruggable drivers.

## Fields

- Kind: Idea
- Last checked: 2026-09-04
- Hypothesis: Adjuvant KRAS peptide/mRNA vaccination reduces recurrence in resected PDAC with MRD-positive disease, with T-cell response magnitude predicting benefit.
- Rationale: Shared neoantigen, low tumour burden post-surgery, ctDNA to enrich and monitor; complements RAS inhibitors that may increase antigen presentation.
- Proposed test: Run a phase 2/3 with ctDNA-positive enrichment and an RFS endpoint; explore combination with daraxonrasib.
- Maturity: early-clinical

## Sources

- Pant et al., AMPLIFY-201: lymph-node-targeted mutant KRAS amphiphile vaccine in pancreatic and colorectal cancer (Nature Medicine 2024): https://doi.org/10.1038/s41591-023-02760-3

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- drugs: [Autogene cevumeran](https://onco.cc/drugs/autogene-cevumeran/), [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/)
- trials: [CodeBreaK 300](https://onco.cc/trials/codebreak-300/), [RASolute 302](https://onco.cc/trials/rasolute-302/), [Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)](https://onco.cc/trials/nct07252232/), [Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma](https://onco.cc/trials/nct07491445/), [Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta](https://onco.cc/trials/nct07621718/)
- key papers: [Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status](https://onco.cc/key-papers/paper-kras-colorectal-j-clin-oncol-2011/), [Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial](https://onco.cc/key-papers/paper-pant-nat-med/), [Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial](https://onco.cc/key-papers/paper-kras-colorectal-j-clin-oncol-2010/), [Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer](https://onco.cc/key-papers/paper-kras-colorectal-j-clin-oncol-2008/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- bottlenecks: [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/)

---
JSON: https://onco.cc/api/v1/entities/idea-shared-kras-vaccine-adjuvant.json